Gilead Sciences was in a position to say, "I told you so," when its first quarter earnings fell a little short of Wall Street expectations Thursday. Profits were still up 63% even as sales of older HIV drugs came in shy of forecasts.
The refusals for elvitegravir and cobicistat on a standalone basis were triggered after inspectors were left shaking their heads following a checkup on Gilead's "documentation and validation of certain quality testing procedures and methods."
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
One of Gilead Sciences' ($GILD) 2012 victories was winning FDA approval for its so-called "Quad" pill for AIDS. Officially dubbed Stribild, the drug puts four HIV fighters into one oral treatment taken once a day.
As anyone in pharma knows, data can be a wonderful thing. Crunching data can also be addictive, like kettle corn or tortilla chips. We here at FierceMarkets can spend hours consuming statistics about our readers and web traffic. Here are the stories that garnered the most web traffic over the past 12 months. More >>
For all of the attention Gilead's Truvada has gotten as the first FDA-approved vaccine to be used to prevent HIV infections, there is little expectation that it will get widespread use in the U.S.
Gilead Sciences ($GILD) hardly had time to celebrate FDA's approval of its new HIV treatment Stribild, aka the Quad. The company announced Stribild's price tag--$28,500--and critics pounced.
The FDA handed Gilead Sciences an approval for its four-in-one HIV drug Quad, extending its blockbuster franchise with a new drug that is expected to find a quick uptake among patients. Next step: Pricing the drug, which could trigger a backlash among payers and patients.